LOXL2—A New Target in Antifibrogenic Therapy?
Open accessThe DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated. Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and/or by promoting its resolution. Therefore, the study of the molecular mechanisms involved in the pathogenesis of liver fibrosis is critical for the development of future antifibrotic therapies. The fibrogenesis process, common to all forms of liver injury, is characterized by the increased deposition of extracellular matrix components (EMCs), including collagen, proteoglycans, and glycoproteins (laminin and fibronectin 2). These changes in the composition of the extracellular matrix components alter their interaction with cell adhesion molecules, influencing the modulation of cell functions (growth, migration, and gene expression). Hepatic stellate cells and Kupffer cells (liver macrophages) are the key fibrogenic effectors. The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action. The research of biochemical changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix. LOXL2 inhibition can decrease cell numbers, proliferation, colony formations, and cell growth, and it can induce cell cycle arrest and increase apoptosis. The development of a new humanized IgG4 monoclonal antibody against LOXL2 could open the window of a new antifibrogenic treatment. The current therapeutic target in patients with liver cirrhosis should focus (after the eradication of the causal agent) on the development of new antifibrogenic drugs. The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“LOX enzymes are widely used to block collagen crosslinking in various preclinical settings [130, 131].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [131]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309 · cited 2×
“Expression levels of LOXL2 were markedly increased in matched adjacent non-tumor tissue compared with levels in tumor tissue samples, and this difference gradually increased with higher histological grade and more advanced hepatocellular tumors [39].”
BackgroundRetractedBataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266 · cited 1×
“In a multicenter randomized placebo-controlled trial involving 651 patients with HBV cirrhosis [27], lamivudine decreased the risk of severe liver complications (7.”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310 · cited 6×
“The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action (inactive macrophage Ly6Clow) [6,23].”
BackgroundInfluentialRecent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“This inflammatory magma induces the transdifferentiation of HSCs to activated HSCs or myofibroblasts that produce substances of the extracellular matrix (collagen types I, III, and IV; fibronectin; laminin; and proteoglycans) [10].”
BackgroundLiver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001 · cited 1×
“, the eradication of hepatitis C) [25].”
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 1×
“The liver parenchyma consists of its own epithelial cells (hepatocytes), endothelial cells, and non-parenchymal cells, including hepatic stellate cells (HSCs) and Kupffer cells (KCs) [2].”
BackgroundBarry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870 · cited 1×
“In 2010, an interesting paper published in Nature Medicine [45] studied the role of LOXL2 in rodent pulmonary/liver fibrosis and cancer models and the benefit of inhibition by a monoclonal antibody (AB0023) AB0023 inhibited vessel branching, number, and length in a dose-dependent manner, with complete inhibition at th…”
BackgroundRoles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677
Baeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609 · cited 4×
“The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action (inactive macrophage Ly6Clow) [6,23].”
BackgroundInfluentialLysyl oxidase: an oxidative enzyme and effector of cell function
Lucero, H. A., & Kagan, H. M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6149-9 · Cited by 607 · cited 2×
“while the N-termini are less conserved among the five members and are supposed to determine their functional role and tissue distribution [36].”
BackgroundNoninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C
Castera, L. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.017 · Cited by 605
Fernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., & Bosch, J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.011 · Cited by 600 · cited 1×
“This neoangiogenesis is the beginning of the generation of portosystemic collateral vessels and portal hypertension syndrome and can lead to the so-called “point of no return” [11,12].”
BackgroundEvolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595 · cited 2×
“This neoangiogenesis is the beginning of the generation of portosystemic collateral vessels and portal hypertension syndrome and can lead to the so-called “point of no return” [11,12].”
BackgroundEvolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581 · cited 4×
“Phagocytosis of apoptotic hepatocytes by myofibroblasts triggers their fibrogenic activation via NADPH oxidase 2 (NOX2) and the JAK/STAT and PI3K/Akt pathways [13].”
BackgroundInfluentialLoomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
Banerjee, R., Pavlides, M., Tunnicliffe, E. M., Piechnik, S. K., Sarania, N., Philips, R., Collier, J. D., Booth, J. C., Schneider, J. E., Wang, L. M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.002 · Cited by 498 · cited 1×
“The number of non-invasive methods has increased in recent years: Transient, vibration-controlled shear wave and magnetic resonance elastography [57,58], acoustic force radiation impulse, magnetic resonance techniques to determine the inflammation and fibrosis score [59] or the quantification of ECM molecules [60], or…”
MethodIssa, R., Zhou, X., Constandinou, C. M., Fallowfield, J., Millward-Sadler, H., Gaca, M. D. A., Sands, E., Suliman, I., Trim, N., & Knorr, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.009 · Cited by 456
Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers
Cassiman, D., Libbrecht, L., Desmet, V., Denef, C., & Roskams, T. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00260-4 · Cited by 410
Harrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384 · cited 2×
“In the NASH patients trial a total of five patients died (two with bridging fibrosis and three with cirrhosis), three of them treated with Simtuzumab and two with placebo [51].”
BackgroundBarron, L., & Wynn, T. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00414.2010 · Cited by 304 · cited 1×
“R gulatory T cells appear to either favor or inhibit fibrogenesis; CD4+ T cells with a Th2 polarization promote fibrogenesis due to the production of IL-4 and IL-13, whereas CD4+ Th1 cells have an antifibrotic effect [18].”
BackgroundIkenaga, N., Peng, Z.-W., Vaid, K. A., Liu, S. B., Yoshida, S., Sverdlov, D. Y., Mikels-Vigdal, A., Smith, V., Schuppan, D., & Popov, Y. V. (2017) · Gut · doi:10.1136/gutjnl-2016-312473 · Cited by 295 · cited 1×
“Given the above findings, a humanized IgG4 monoclonal antibody against LOXL2, SIMTUZUMAB® (Gilead Sciences SA) has been developed [46].”
BackgroundRaghu, G., Brown, K. K., Collard, H. R., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Martinez, F. J., Noble, P. W., Song, J. W., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30421-0 · Cited by 278 · cited 1×
“The preliminary results did not support the use of Simtuzumab for patients with this disease because it did not improve progression-free survival [40,47].”
ResultPortal fibroblasts: Underappreciated mediators of biliary fibrosis†
Dranoff, J. A., & Wells, R. G. (2010) · Hepatology · doi:10.1002/hep.23405 · Cited by 273 · cited 2×
“Activated m ofibroblasts derive from both activated hepatic stellate cells and portal fibroblasts, which are the principal producers of scar but are also involved in fibrosis regression through the release of ECM-degrading proteases [14,15].”
BackgroundLens, S., Alvarado-Tapias, E., Mariño, Z., Londoño, M.-C., LLop, E., Martinez, J., Fortea, J. I., Ibañez, L., Ariza, X., Baiges, A., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.016 · Cited by 271
Self-citationWong, C. C.-L., Tse, A. P.-W., Huang, Y.-P., Zhu, Y.-T., Chiu, D. K.-C., Lai, R. K.-H., Au, S. L.-K., Kai, A. K.-L., Lee, J. M.-F., Wei, L. L., et al. (2014) · Hepatology · doi:10.1002/hep.27320 · Cited by 253 · cited 1×
“The involvement of LOXL2 in the transformation of the extracellular matrix in a “prooncogenic” tissue that favors the metastatic niche of intrahepatic HCC has been recently published in Hepatology [38].”
BackgroundProcopet, B., Berzigotti, A., Abraldes, J. G., Turon, F., Hernandez-Gea, V., García-Pagán, J. C., & Bosch, J. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.007 · Cited by 221 · cited 1×
“The number of non-invasive methods has increased in recent years: Transient, vibration-controlled shear wave and magnetic resonance elastography [57,58], acoustic force radiation impulse, magnetic resonance techniques to determine the inflammation and fibrosis score [59] or the quantification of ECM molecules [60], or…”
MethodNovo, E., Cannito, S., Zamara, E., di Bonzo, L. V., Caligiuri, A., Cravanzola, C., Compagnone, A., Colombatto, S., Marra, F., Pinzani, M., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060887 · Cited by 220 · cited 4×
“The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action (inactive macrophage Ly6Clow) [6,23].”
BackgroundInfluentialBenson, A. B., Wainberg, Z. A., Hecht, J. R., Vyushkov, D., Dong, H., Bendell, J., & Kudrik, F. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0024 · Cited by 195 · cited 1×
“Findings for colorectal and pancreatic cancer did not support a clear clinical benefit [48,49].”
BackgroundMuir, A. J., Levy, C., Janssen, H. L. A., Montano‐Loza, A. J., Shiffman, M. L., Caldwell, S., Luketic, V., Ding, D., Jia, C., McColgan, B. J., et al. (2019) · Hepatology · doi:10.1002/hep.30237 · Cited by 195 · cited 1×
“In PSC, Simtuzumab or placebo treatment for 96 weeks did not lead to any significant reductions in Ishak fibrosis stage, progression to cirrhosis, or frequency of clinical events, regardless of the dose (injections of 75 mg or 125 mg) [53].”
BackgroundSerum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression
Chien, J. W., Richards, T. J., Gibson, K. F., Zhang, Y., Lindell, K. O., Shao, L., Lyman, S. K., Adamkewicz, J. I., Smith, V., Kaminski, N., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00141013 · Cited by 171 · cited 3×
“The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, and down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure [7,40].”
BackgroundResultVascular mediators in the injured liver
Rockey, D. C. (2003) · Hepatology · doi:10.1053/jhep.2003.50044 · Cited by 168 · cited 2×
“NO modulates intrahepatic resistance by stimulating a soluble guanylate cyclase that decreases Ca2+ levels and provoking vasodilation and HSC relaxation [16].”
BackgroundMolecular MRI of collagen to diagnose and stage liver fibrosis
Fuchs, B. C., Wang, H., Yang, Y., Wei, L., Polasek, M., Schühle, D. T., Lauwers, G. Y., Parkar, A., Sinskey, A. J., Tanabe, K. K., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.026 · Cited by 160 · cited 1×
“The number of non-invasive methods has increased in recent years: Transient, vibration-controlled shear wave and magnetic resonance elastography [57,58], acoustic force radiation impulse, magnetic resonance techniques to determine the inflammation and fibrosis score [59] or the quantification of ECM molecules [60], or…”
MethodD’Ambrosio, R., Aghemo, A., Fraquelli, M., Rumi, M. G., Donato, M. F., Paradis, V., Bédossa, P., & Colombo, M. G. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.013 · Cited by 145 · cited 1×
“Another issue to be taken into account in the method is the validity of elastographic (mainly Fibroscan®) and other serological methods in the follow-up of post-SVR fibrosis and steatosis [32,33].”
MethodHecht, J. R., Benson, A. B., Vyushkov, D., Yang, Y., Bendell, J., & Verma, U. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0479 · Cited by 134
Origin and evolution of lysyl oxidases
Grau-Bové, X., Ruiz-Trillo, I., & Rodriguez-Pascual, F. (2015) · Scientific Reports · doi:10.1038/srep10568 · Cited by 124 · cited 2×
“Recently, the research of biochemical changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix [35].”
BackgroundRole of magnetic resonance elastography in compensated and decompensated liver disease
Asrani, S. K., Talwalkar, J. A., Kamath, P. S., Shah, V. H., Saracino, G., Jennings, L. W., Gross, J. B., Venkatesh, S. K., & Ehman, R. L. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.016 · Cited by 94 · cited 1×
“The number of non-invasive methods has increased in recent years: Transient, vibration-controlled shear wave and magnetic resonance elastography [57,58], acoustic force radiation impulse, magnetic resonance techniques to determine the inflammation and fibrosis score [59] or the quantification of ECM molecules [60], or…”
MethodMononuclear cells in liver fibrosis
Marra, F., Aleffi, S., Galastri, S., & Provenzano, A. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0169-0 · Cited by 90
García–Tsao, G., Fuchs, M. A., Shiffman, M. L., Borg, B. B., Pyrsopoulos, N., Shetty, K., Gallegos-Orozco, J. F., Reddy, K. R., Feyssa, E. L., Chan, J. L., et al. (2018) · Hepatology · doi:10.1002/hep.30199 · Cited by 88 · cited 1×
“The use of ASK 1 inhibitor (selonsertib) [52] or a pan-caspase inhibitor such as emricasan [54] could be potential therapeutic options for liver fibrosis and portal hypertension.”
BackgroundTranslating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies
Rockey, D. C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.01.005 · Cited by 84 · cited 2×
“Therefore, the study of the molecular and cellular mechanisms involved in fibrogenesis is critical for establishing future antifibrotic therapies [4,5].”
BackgroundDongiovanni, P., Meroni, M., Baselli, G., Bassani, G. A., Rametta, R., Pietrelli, A., Maggioni, M., Facciotti, F., Trunzo, V., Badiali, S., et al. (2017) · Clinical Science · doi:10.1042/cs20170175 · Cited by 82
Assessment of liver fibrosis progression and regression by a serological collagen turnover profile
Karsdal, M. A., Hjuler, S. T., Luo, Y., Rasmussen, D. G. K., Nielsen, M. J., Nielsen, S. H., Leeming, D. J., Goodman, Z. D., Arch, R. H., Patel, K., et al. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00158.2018 · Cited by 57
Lalazar, G., Pappo, O., Hershcovici, T., Hadjaj, T., Shubi, M., Ohana, H., Hemed, N., & Ilan, Y. (2008) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.01007.x · Cited by 53
Th17 Cells Regulate Liver Fibrosis by Targeting Multiple Cell Types: Many Birds With One Stone
Gao, B., & Waisman, A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.031 · Cited by 33
Puente, Á., Cabezas, J., Arias, M. J. L., Arias, M., Estébanez, Á., Casafont, F., Fábrega, E., & Crespo, J. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4235/2016 · Cited by 21 · cited 1×
“The regression of hyperdynamic circulation, activation of vasoactive systems, and involution of portosystemic collateral networks are aspects currently under evaluation [30].”
BackgroundSelf-citationStravitz, R. T., & Ilan, Y. (2016) · Liver International · doi:10.1111/liv.13268 · Cited by 19
Research works printed but not linked: 6
- Cabezas, 2017, Impact of SVR in the development of all complications and fibrosis regression in a cohort of patients treated with interferon-base Triple Therapy and Direct Acting Antiviral, Hepatology, 66, 218A
- Bosch, 2015, Correlation between noninvasive markers of fibrosis and the hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), Hepatology, 62, 120A
- Afdha, 2015, Serum lysyl oxidase-like-2 (sLOXL2) is correlated with the hepatic venous pressure gradient (HVPG) in patients with cirrhosis due to hepatitis C, Hepatology, 62, 121A
- Bourliere, 2015, Changes in liver stiffness by transient elastography (TE) and serum lysyl oxidase-like-2 (sLOXL2) in patients with cirrhosis treated with ledipasvir/sofosbuvir (LDV/SOF)-based therapy, Hepatology, 62, 123A
- Puente, 2019, Influence of the metabolic syndrome on fibrosis regression regulated by LOXL2 after sustained virologycal response, Gastroenterol. Hepatol., 42, 123
- Tatal, 2013, Simtuzumab, an antifibrotic monoclonal antibody against lysyl oxidase like 2, appears safe and well tolerated in patients with liver disease of diverse etiology, J. Hepatol., 58, S409
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“For example, LOX enzymes are widely used to block collagen crosslinking in various preclinical settings [130, 131] .”
BackgroundLysyl oxidases: from enzyme activity to extracellular matrix cross-links
Vallet, S. D., & Ricard-Blum, S. (2019) · Essays in Biochemistry · doi:10.1042/ebc20180050 · Cited by 335
TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
“ECM synthesis and degradation, and activities of ECM stabilizing cross-linking enzymes, increase with accumulation of fi broblasts and myo fi broblasts, and progression of fi brotic disease [37 – 39].”
BackgroundChen, W., Yang, A., Jia, J., Popov, Y. V., Schuppan, D., & You, H. (2020) · Hepatology · doi:10.1002/hep.31236 · Cited by 284
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma
Tschumperlin, D. J., & Lagares, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107575 · Cited by 159
Metadata
- Authors
- Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J.
- Affiliations
- Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain
- Universidad de Cantabria (ES)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-02
- Volume
- 20
- Issue
- 7
- Pages
- 1634
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6480111
- OpenAlex
- W2933665664
- Cited by
- 79
- References
- 58
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 13 · 2023: 11 · 2022: 12 · 2021: 14 · 2020: 13 · 2019: 6
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- LOXL2, liver fibrosis, antifibrotic therapy, liver cirrhosis, extracellular matrix, collagen deposition, hepatic stellate cells, Kupffer cells, monoclonal antibodies, fibrosis reversibility, portal pressure
- MeSH terms
- Animals, Humans, Liver Cirrhosis, Protein-Lysine 6-Oxidase, Models, Biological, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.